Special Issue

Diagnosis, Drug Resistance Mechanism and Molecular Epidemiology of Clinical Pathogens

Message from the Guest Editors

Pathogens are difficult-to-fight microorganisms and viruses. In recent years, many different types of molecules and methods were discovered and released to prevent and diagnose diseases. Regardless of the amount of effort put in the scientific part of the community to fight these diseases, we still face new and old pathogens causing a lot of social and economic losses to the world population. Therefore, new diagnostic methodologies and new molecules remain a real challenge to fighting these pathogens in a faster and more efficient way. This Special Issue plans to give an overview of the most recent advances in the field of Diagnosis, Drug Resistance Mechanism, and Molecular Epidemiology of Clinical Pathogens and their applications in diverse areas. This Special Issue is aimed at providing selected contributions on advances in molecular diagnosis, point of care diagnosis, whole genome sequence analysis, molecular characterization, antimicrobial agents and antibiofilm activity, as well as antiviral agents concerning fighting and accelerating the diagnosis and treatment of diseases caused by these lethal agents.

Guest Editors

Dr. Fabio Aguiar-Alves

Prof. Dr. Bruno de araujo Penna

Dr. Renata Freire Alves Pereira

Deadline for manuscript submissions

closed (20 August 2024)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/155513

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

